Revolution Medicines, Inc. (RVMDW) shareholders
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
10M
Shares held, 13F filers
Institutional holders
22
3 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 153 sales
Net sold $152.50M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dunn Hannah E. Joint filing with Wehrly, Mark C. (7.50%), Dreyfuss, Philip D. (7.50%) and 13 more | 14,596,149 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Kim, David T. Joint filing with Dapice Joshua J. (6.40%), Dreyfuss, Philip D. (6.40%) and 13 more | 13,564,149 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Saito Edric C. Joint filing with Wehrly, Mark C. (7.90%), Dreyfuss, Philip D. (7.90%) and 15 more | 13,262,045 | 7.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 12,201,395 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (5.30%), Felix J. Baker (5.30%) and 1 more | 11,443,357 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Warren, John R. Joint filing with Wehrly, Mark C. (6.80%), Dreyfuss, Philip D. (6.80%) and 14 more | 11,331,045 | 6.80% | 13G (passive) amendment | Sep 30, 2024 |
| JANUS HENDERSON GROUP Ltd. | 10,736,145 | 5.10% | 13G (passive) | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.00%) | 9,401,687 | 5.00% | 13G (passive) | Sep 30, 2025 |
| Julian C. Baker Joint filing with Baker Bros. Advisors (GP) LLC (5.00%), Baker Bros. Advisors LP (5.00%) and 1 more | 9,364,972 | 5.00% | 13G (passive) | Jun 30, 2025 |
| Spokes, Andrew J. M. Joint filing with Dapice Joshua J. (5.10%), Dreyfuss, Philip D. (5.10%) and 13 more | 8,376,225 | 5.10% | 13G (passive) | Apr 12, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RVMDW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| LMR Partners LLP | 5,066,598 | – | $47.52M | +1,228,574 | 0.18% |
| D. E. Shaw & Co., Inc. | 1,580,345 | – | $14.86M | – | 0.01% |
| Sculptor Capital LP | 709,670 | – | $6.66M | −249,152 | 0.05% |
| Price T Rowe Associates Inc /Md/ | 579,550 | – | $5.45M | – | 0.00% |
| Caption Management, LLC | 517,685 | – | $4.86M | – | 0.02% |
| Adage Capital Partners Gp, L.L.C. | 500,000 | – | $4.69M | – | 0.01% |
| Perceptive Advisors LLC | 250,000 | – | $2.34M | – | 0.04% |
| Bleichroeder LP | 200,000 | – | $1.88M | – | 0.34% |
| Wolverine Asset Management LLC | 154,544 | – | $1.45M | −16,154 | 0.01% |
| Farallon Capital Management LLC | 120,085 | – | $1.13M | – | 0.01% |
| Warberg Asset Management LLC | 94,797 | – | $889.19K | New | 0.16% |
| Css LLC/Il | 78,367 | – | $6.61M | +60,862 | 0.26% |
| DLK Investment Management, LLC | 77,000 | – | $7.86K | New | 0.00% |
| Weiss Asset Management LP | 73,640 | – | $692.22K | – | 0.01% |
| TD Asset Management Inc | 40,636 | – | $381.98K | – | 0.00% |
| Rangeley Capital, LLC | 25,000 | – | $4.68M | New | 4.28% |
| Driehaus Capital Management LLC | 20,000 | – | $188.00K | – | 0.00% |
| UBS Group AG | 2,461 | – | $23.08K | +1,575 | 0.00% |
| Morgan Stanley | 2,216 | – | $20.79K | – | 0.00% |
| TD Waterhouse Canada Inc. | 448 | – | $4.12K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 22 | 10M | 3 / 3 | 3 / 4 | 1M | 1M |
| Q1 2026 | 23 | 10M | 2 / 6 | 5 / 3 | 2M | 1M |
| Q4 2025 | 24 | 9M | 3 / 3 | 3 / 1 | 1M | 0M |
| Q3 2025 | 22 | 8M | 0 / 1 | 3 / 1 | 0M | 0M |
| Q2 2025 | 23 | 8M | 1 / 3 | 3 / 2 | 1M | 0M |
| Q1 2025 | 24 | 8M | 3 / 3 | 2 / 3 | 0M | 0M |
| Q4 2024 | 24 | 8M | 3 / 3 | 1 / 4 | 3M | 0M |
| Q3 2024 | 25 | 5M | 1 / 1 | 2 / 1 | 0M | 2M |
| Q2 2024 | 25 | 7M | 2 / 2 | 4 / 1 | 0M | 0M |
| Q1 2024 | 24 | 7M | 3 / 1 | 4 / 1 | 2M | 0M |
| Q4 2023 | 22 | 5M | 22 / 0 | 0 / 0 | 5M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held RVMDW in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RVMDW | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price New Horizons Fund, Inc. | 302,672 | – | $2.85M | 0.02% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 198,505 | – | $1.87M | 0.02% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Portfolio | 11,096 | – | $104.30K | 0.01% | Jun 30, 2026 |
| Health Sciences Trust | 4,502 | – | $42.32K | 0.02% | Jun 30, 2026 |
| EQ/T.Rowe Price Health Sciences Portfolio | 3,127 | – | $29.39K | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Mark A. Goldsmith | See Remarks, Director | 314,766 | Sep 18, 2026 |
| Jeff Cislini | SVP & General Counsel | 51,776 | Sep 29, 2026 |
| Anthony Mancini | See Remarks | 42,886 | Sep 28, 2026 |
| Alan B. Sandler | Chief Development Officer | 53,204 | Sep 18, 2026 |
| Stephen Michael Kelsey | See Remarks | 286,307 | Sep 18, 2026 |
| Margaret A. Horn | Chief Operating Officer | 154,571 | Sep 18, 2026 |
| Jack Anders | Chief Financial Officer | 123,208 | Sep 18, 2026 |
| Xiaolin Wang | See Remarks | 116,063 | Mar 19, 2026 |
| Lin Wei | Chief Medical Officer | 101,366 | Mar 19, 2026 |
| Elizabeth M. Anderson | Director | 31,423 | Sep 24, 2026 |
| Lorence H. Kim | Director | 10,136 | Sep 10, 2026 |
| Sushil Patel | Director | 24,078 | Jul 1, 2026 |
| Sandra Horning | Director | 97,765 | Jun 23, 2026 |
| Flavia Borellini | Director | 26,215 | Jun 23, 2026 |
| Alexis Borisy | Director | 2,340,075 | Jun 23, 2026 |
| Frank Clyburn | Director | 10,929 | Jun 23, 2026 |
| Thilo Schroeder | Director | 7,601,087 | Dec 9, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeff Cislini SVP & General Counsel | Sep 25, 2026 | Sale(10b5-1 plan) | −765 | $207.32 | $158.60K | 51,776 |
| Anthony Mancini See Remarks | Sep 25, 2026 | Option exercise | +3,121 | $33.62 | $104.93K | 42,886 |
| Anthony Mancini See Remarks | Sep 25, 2026 | Sale(10b5-1 plan) | −3,121 | $200.54 | $625.89K | 39,765 |
| Anthony Mancini See Remarks | Sep 24, 2026 | Sale(10b5-1 plan) | −587 | $200.00 | $117.40K | 39,765 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −1,500 | $194.59 | $291.89K | 4,433 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Option exercise | +5,070 | $1.12 | $5.68K | 14,476 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −910 | $191.85 | $174.58K | 13,566 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −4,985 | $192.54 | $959.81K | 8,581 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −2,648 | $193.44 | $512.23K | 5,933 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −100 | $195.15 | $19.52K | 4,333 |
| Anthony Mancini See Remarks | Sep 18, 2026 | Sale(10b5-1 plan) | −1,764 | $196.94 | $347.40K | 40,352 |
| Jeff Cislini SVP & General Counsel | Sep 16, 2026 | Sale(10b5-1 plan) | −3,314 | $199.30 | $660.48K | 52,541 |
| Jeff Cislini SVP & General Counsel | Sep 16, 2026 | Sale(10b5-1 plan) | −52 | $195.01 | $10.14K | 55,855 |
| Alan B. Sandler Chief Development Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −5 | $194.96 | $975 | 53,204 |
| Alan B. Sandler Chief Development Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −336 | $199.30 | $66.96K | 52,868 |
| Jack Anders Chief Financial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −61 | $195.00 | $11.90K | 123,208 |
| Jack Anders Chief Financial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −3,992 | $199.30 | $795.61K | 119,216 |
| Margaret A. Horn Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −76 | $195.01 | $14.82K | 154,571 |
| Margaret A. Horn Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −4,891 | $199.30 | $974.78K | 149,680 |
| Mark A. Goldsmith See Remarks, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −13,775 | $199.30 | $2.75M | 253,342 |
| Mark A. Goldsmith See Remarks, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −213 | $195.01 | $41.54K | 267,117 |
| Anthony Mancini See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −27 | $195.05 | $5.27K | 43,863 |
| Anthony Mancini See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −1,747 | $199.30 | $348.18K | 42,116 |
| Stephen Michael Kelsey See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −5,484 | $199.30 | $1.09M | 286,307 |
| Stephen Michael Kelsey See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −85 | $195.01 | $16.58K | 291,791 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Option exercise | +40,031 | $40.74 | $1.63M | 384,407 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Option exercise | +52,500 | $42.45 | $2.23M | 344,376 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −800 | $198.55 | $158.84K | 383,607 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −11,833 | $200.11 | $2.37M | 371,774 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −13,368 | $200.78 | $2.68M | 358,406 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −21,447 | $201.75 | $4.33M | 336,959 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −18,869 | $203.06 | $3.83M | 318,090 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −17,949 | $203.87 | $3.66M | 300,141 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −4,995 | $204.84 | $1.02M | 295,146 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −3,270 | $205.81 | $673.00K | 291,876 |
| Anthony Mancini See Remarks | Sep 10, 2026 | Sale(10b5-1 plan) | −5,530 | $204.14 | $1.13M | 47,789 |
| Anthony Mancini See Remarks | Sep 10, 2026 | Option exercise | +9,363 | $33.62 | $314.78K | 59,338 |
| Anthony Mancini See Remarks | Sep 10, 2026 | Sale(10b5-1 plan) | −6,019 | $203.28 | $1.22M | 53,319 |
| Anthony Mancini See Remarks | Sep 10, 2026 | Sale(10b5-1 plan) | −300 | $207.17 | $62.15K | 43,890 |
| Anthony Mancini See Remarks | Sep 10, 2026 | Sale(10b5-1 plan) | −1,179 | $206.10 | $242.99K | 44,190 |
| Anthony Mancini See Remarks | Sep 10, 2026 | Sale(10b5-1 plan) | −2,420 | $205.05 | $496.22K | 45,369 |
| Lorence H. Kim Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,853 | $209.56 | $597.87K | 8,945 |
| Lorence H. Kim Director | Sep 8, 2026 | Sale(10b5-1 plan) | −3,844 | $211.36 | $812.47K | 371 |
| Lorence H. Kim Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,730 | $210.50 | $995.67K | 4,215 |
| Lorence H. Kim Director | Sep 8, 2026 | Sale(10b5-1 plan) | −371 | $212.27 | $78.75K | 0 |
| Lorence H. Kim Director | Sep 8, 2026 | Sale(10b5-1 plan) | −3,587 | $208.55 | $748.07K | 11,798 |
| Lorence H. Kim Director | Sep 8, 2026 | Sale(10b5-1 plan) | −999 | $207.33 | $207.12K | 15,385 |
| Lorence H. Kim Director | Sep 8, 2026 | Sale(10b5-1 plan) | −706 | $206.60 | $145.86K | 16,384 |
| Lorence H. Kim Director | Aug 31, 2026 | Sale(10b5-1 plan) | −2,128 | $205.19 | $436.64K | 17,715 |
| Lorence H. Kim Director | Aug 31, 2026 | Sale(10b5-1 plan) | −12,919 | $202.48 | $2.62M | 53,274 |
| Lorence H. Kim Director | Aug 31, 2026 | Sale(10b5-1 plan) | −7,271 | $204.35 | $1.49M | 19,843 |
| Lorence H. Kim Director | Aug 31, 2026 | Sale(10b5-1 plan) | −26,160 | $203.55 | $5.32M | 27,114 |
| Lorence H. Kim Director | Aug 31, 2026 | Sale(10b5-1 plan) | −6,597 | $201.47 | $1.33M | 66,193 |
| Lorence H. Kim Director | Aug 31, 2026 | Sale(10b5-1 plan) | −300 | $200.56 | $60.17K | 72,790 |
| Lorence H. Kim Director | Aug 31, 2026 | Sale(10b5-1 plan) | −625 | $206.15 | $128.84K | 17,090 |
| Mark A. Goldsmith See Remarks, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −136 | $210.40 | $28.61K | 61,796 |
| Mark A. Goldsmith See Remarks, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −1,351 | $209.28 | $282.74K | 61,932 |
| Mark A. Goldsmith See Remarks, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −951 | $208.36 | $198.15K | 63,283 |
| Mark A. Goldsmith See Remarks, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −190 | $207.25 | $39.38K | 64,234 |
| Mark A. Goldsmith See Remarks, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −3,621 | $212.08 | $767.94K | 267,330 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+106.3%
From 0M shares
Short volume, 20 days
59.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Revolution Medicines's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,019 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Alan B. Sandler Officer | Sep 29, 2026 | 6,309 | $1.27M | Sep 29, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 25, 2026 | 9,363 | $1.87M | Sep 25, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 24, 2026 | 587 | $111.96K | Sep 24, 2026 | Restricted Stock Units |
| Elizabeth M. Anderson Director | Sep 22, 2026 | 15,080 | $2.91M | Sep 22, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 18, 2026 | 1,764 | $347.40K | Sep 18, 2026 | Restricted Stock Units |
| Alan B. Sandler Officer | Sep 15, 2026 | 331 | $67.45K | Sep 15, 2026 | RSU vesting |
| Anthony Mancini Officer | Sep 15, 2026 | 2,377 | $484.36K | Sep 15, 2026 | RSU vesting |
| Stephen Michael Kelsey Officer | Sep 15, 2026 | 5,415 | $1.10M | Sep 15, 2026 | RSU vesting |
| Margaret A. Horn Officer | Sep 15, 2026 | 4,830 | $984.21K | Sep 15, 2026 | RSU vesting |
| Mark A. Goldsmith Officer, Director | Sep 15, 2026 | 13,603 | $2.77M | Sep 15, 2026 | RSU vesting |
| Jeff Cislini Officer | Sep 15, 2026 | 3,272 | $666.74K | Sep 15, 2026 | RSU vesting |
| Jack Anders Officer | Sep 15, 2026 | 3,939 | $802.65K | Sep 15, 2026 | RSU vesting |
| Stephen Michael Kelsey Officer | Sep 11, 2026 | 92,531 | $18.82M | Sep 11, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 10, 2026 | 15,448 | $3.21M | Sep 10, 2026 | Exercise of Stock Options |
| Lorence H. Kim Affiliate | Aug 31, 2026 | 73,090 | $15.19M | Aug 31, 2026 | Purchase |